Physician

Amit Indravadan Shah, M.D.

According to 2025 Medicare claims, Amit Shah, M.D. (NPI: 1407850449) practices medical oncology in the Sebring, FL market, with the plurality of this provider's patient population coming from Highlands, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33870-1204.

Shah's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,134 traditional Medicare patients, billed 248,876 HCPCS/CPT codes, and received $3,363,930 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 885 prescription claims across 185 beneficiaries totaling $3,374,424 in drug costs, led by Revlimid (Lenalidomide). DME data shows 124 claims. Open Payments data shows 190 records totaling $4,265. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $2,011,313 to $3,374,424. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $14,180 to $4,735.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,362	419,123	$4,354,691
2016	1,442	459,338	$4,579,427
2017	1,462	409,367	$4,407,316
2018	1,371	379,083	$4,612,518
2019	1,353	332,126	$3,973,568
2020	1,109	307,831	$3,344,899
2021	1,139	279,320	$3,164,673
2022	1,058	247,493	$3,381,139
2023	1,235	294,246	$3,962,500
2024	1,134	248,876	$3,363,930

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	269	1,201	$2,011,313
2016	295	1,411	$2,618,049
2017	308	1,314	$2,684,226
2018	267	1,214	$2,973,476
2019	251	1,097	$3,133,674
2020	221	1,157	$3,317,638
2021	237	1,235	$4,219,641
2022	193	953	$3,664,915
2023	204	882	$2,966,849
2024	185	885	$3,374,424

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	49	233	$12,200
2016	24	160	$28,127
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	18	$1,445
2023	N/R	47	$2,303
2024	N/R	124	$42,398

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	433	790	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	381	726	$64
96372	Injection of drug or substance under skin or into muscle	274	816	$10
36415	Insertion of needle into vein for collection of blood sample	699	1,688	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	659	1,701	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	72	1,890	$1,216,057
Jakafi	Ruxolitinib Phosphate	17	510	$286,407
Brukinsa	Zanubrutinib	18	540	$158,566
Octagam	Immun Globg(Igg)/Malt/Iga Ov50	13	368	$65,846
Xarelto	Rivaroxaban	22	1,200	$22,017

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	15	$37,211
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	27	$2,063
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	15	$999
J7605	Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms	N	N/R	11	$786
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	N	N/R	11	$593

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	190	$4,265	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amit Indravadan Shah, M.D.?

Tedicare shows public-source Medicare data for Amit Indravadan Shah, M.D. (NPI 1407850449), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amit Indravadan Shah, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Amit Indravadan Shah, M.D.?

Amit Indravadan Shah, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Amit Indravadan Shah, M.D. have Open Payments data?

Amit Indravadan Shah, M.D. has 190 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.